MEDICAL POLICY

POLICY
RELATED POLICIES
POLICY GUIDELINES
DESCRIPTION
SCOPE
BENEFIT APPLICATION
RATIONALE
REFERENCES
CODING
APPENDIX
HISTORY

Genetic Testing for Familial Alzheimer’s Disease

Number 12.04.13

Effective Date December 4, 2013

Revision Date(s) 11/11/13; 08/09/11; 02/09/10; 02/10/09; 01/08/08; 05/09/06; 05/10/05; 08/12/03; 12/21/00; 09/07/99

Replaces 2.04.13

Policy

Genetic testing for the diagnosis or risk assessment of Alzheimer’s disease is considered investigational. Genetic testing includes, but is not limited to, testing for the apolipoprotein E epsilon 4 allele, presenilin genes, amyloid precursor gene, or TREM2.

Related Policies

2.04.14

Biochemical Markers of Alzheimer's Disease

12.04.91

General Approach to Genetic Testing

Policy Guidelines

Genetic testing for Alzheimer’s disease may be offered along with cerebral spinal fluid (CSF) levels of the Tau protein and AB-42 peptide (see Related Policies). This group of tests may be collectively referred to as the ADMark Profile, offered by Athena Diagnostics (Worcester, Mass.).

Effective in 2013, there is CPT coding to more specifically report PSEN and APP testing.

CPT code 81405 includes:

PSEN1 (presenilin 1) (e.g., Alzheimer disease), full gene sequence.

CPT code 81406 includes:

APP (amyloid beta [A4] precursor protein) (e.g., Alzheimer disease), full gene sequence, and PSEN2 (presenilin 2 [Alzheimer disease 4]) (e.g., Alzheimer disease), full gene sequence.

Description

Alzheimer’s disease (AD) is the most common cause of dementia in elderly patients. Earlyonset AD is much less common, but can occur in non-elderly individuals. For late-onset AD, there is a component of risk that runs in families, suggesting the contribution of genetic factors. Early onset Alzheimer’s has a stronger component of family risk, with clustering in families, thus suggesting an inherited genetic mutation.

Background

Alzheimer’s disease (AD) is commonly associated with a family history; 40% of patients with AD have a least one other afflicted first-degree relative. Numerous genes have been associated with late-onset AD, while mutations in chromosomes 1, 14, and 21 have been associated with early onset familial AD. (1)

Susceptibility Polymorphism at the Apolipoprotein E (APOE) Gene

The APOE lipoprotein is a carrier of cholesterol produced in the liver and brain glial cells. The APOE gene has 3 alleles—epsilon 2, 3, and 4— with the epsilon 3 allele being the most common. Individuals carry 2 APOE alleles. The presence of at least 1 epsilon 4 allele is associated with a 1.2- to 3-fold increased risk of AD, depending on the ethnic group. Among those homozygous for epsilon 4 (about 2% of the population), the risk of AD is higher than for those heterozygous for epsilon 4. The mean age of onset of AD is at about age 68 years for epsilon 4 homozygotes, about 77 years for heterozygotes, and about 85 years for those with no epsilon 4 alleles. About half of patients with sporadic AD carry an epsilon 4 allele. However, not all patients with the allele develop AD. The epsilon 4 allele represents a risk factor for AD rather than a disease-causing mutation. In the absence of APOE testing, first-degree relatives of an individual with sporadic or familial AD are estimated to have a 2- to 4-fold greater risk of developing AD than the general population. (2) There is evidence of possible interactions between epsilon 4 alleles, other risk factors for AD [e.g., risk factors for cerebrovascular disease such as smoking, hypertension, hypercholesterolemia, and diabetes (3)], and a higher risk of developing AD. However, it is not clear that all risk factors have been taken into account in such studies, including the presence of polymorphisms in other genes that may increase the risk of AD.

Genetic Mutations

Individuals with early onset familial AD (i.e., before age 65 years but as early as 30 years) form a small subset of AD patients. AD within families of these patients may show an autosomal dominant pattern of inheritance. Pathogenic mutations in three genes have been identified in affected families: amyloid -beta precursor protein gene (APP), presenilin1 (PSEN1) gene, and presenilin2 (PSEN2) gene. APP and PSEN1 mutations have 100% penetrance absent death from other causes, while PSEN2 has 95% penetrance. A variety of mutations within these genes has been associated with AD; mutations in PSEN1 appear to be the most common. While only 35% of all patients with AD have early onset disease, pathogenic mutations have been identified in up to 70% or more of these patients. Identifiable genetic mutations are, therefore, rare causes of AD.

Testing for the APOE4 allele among patients with late -onset AD and for APP, PSEN1, or PSEN2 mutations in the rare patient with earlyonset AD have been investigated as an aid in diagnosis of patients presenting with symptoms suggestive of AD, or as a technique for risk assessment in asymptomatic patients with a family history of AD. Mutations in PSEN1 and PSEN2 are specific for AD; APP mutations are also found in cerebral hemorrhagic amyloidosis of the Dutch type, a disease in which dementia and brain amyloid plaques are uncommon.

Susceptibility Testing at the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Gene

Recent studies identified rs75932628-T, a rare functional substitution for R47H of TREM2, as a heterozygous risk variant for late-onset AD. (4, 5) On chromosome 6p21.1, at position 47 (R47H), the T allele of rs75932628, encodes a histidine substitute for arginine in the gene that encodes TREM2.

TREM2 is highly expressed in the brain and is known to have a role in regulating inflammation and phagocytosis. TREM2 may serve a protective role in the brain by suppressing inflammation and clearing it of cell debris, amyloids and toxic products. A decrease in the function of TREM2 would allow inflammation in the brain to increase and may be a factor in the development of AD. The effect size of the TREM2 variant confers a risk of AD that is similar to the APOE epsilon 4 allele, although it occurs less frequently.

Diagnosis of Alzheimer’s Disease

The diagnosis of Alzheimer’s disease (AD) is divided into three categories: possible, probable, and definite AD. (6) A diagnosis of definite AD requires postmortem confirmation of AD pathology, documenting the presence of extracellular beta amyloid plaques and intraneuronal neurofibrillary tangles in the cerebral cortex. As a result, a diagnosis of definite AD cannot be made during life, and the diagnosis of probable or possible AD is made on clinical grounds. (7) Probable AD dementia is diagnosed clinically when the patient meets core clinical criteria for dementia and has a typical clinical course for AD. Criteria for diagnosis of probable AD have been developed by the National Institute on Aging and the Alzheimer’s Association. (6) These criteria require evidence of a specific pattern of cognitive impairment, a typical clinical course, and exclusion of other potential etiologies, as follows:

  • Cognitive impairment
  • Cognitive impairment established by history from patient and a knowledgeable informant, plus objective assessment by bedside mental status examination or neuropsychological testing
  • Cognitive impairment involving a minimum of two of the following domains:
  • Impaired ability to acquire and remember new information
  • Impaired reasoning and handling of complex tasks, poor judgment
  • Impaired visuospatial abilities
  • Impaired language functions
  • Changes in personality, behavior, or comportment
  • Initial and most prominent cognitive deficits are one of the following:
  • Amnestic presentation
  • Nonamnestic presentations, either a language presentation with prominent word-finding deficits; a visuospatial presentation with visual cognitive defects; or a dysexecutive presentation with prominent impairment of reasoning, judgment, and/or problem solving.
  • Clinical course
  • Insidious onset
  • Clear-cut history of worsening over time
  • Interference with ability to function at work or usual activities
  • Decline from previous level of functioning and performing
  • Exclusion of other disorders
  • Cognitive decline not explained by delirium or major psychiatric disorder
  • No evidence of other active neurologic disease, including substantial cerebrovascular disease or dementia with Lewy bodies.
  • Lack of prominent features of variant frontotemporal dementia or primary progressive aphasia.
  • No medication use with substantial effects on cognition.

A diagnosis of possible AD dementia is made when the patient meets most of the AD criteria, but has an atypical course or an etiologically mixed presentation. (6) This may consist of an atypical onset (e.g., sudden onset) or atypical progression. A diagnosis of possible AD is also made when there is another potentially causative systemic or neurologic disorder that is not thought to be the primary etiology of dementia.

Mild cognitive impairment (MCI) is a precursor of AD in many instances. MCI may be diagnosed when there is a change in cognition, but not sufficient impairment for the diagnosis of dementia. (8) Features of MCI are evidence of impairment in one or more cognitive domains, and preservation of independence in functional abilities. In some patients, MCI may be a predementia phase of AD. Patients with MCI may undergo ancillary testing (e.g., neuroimaging, laboratory studies, and neuropsychological assessment) to rule out vascular, traumatic, and medical causes of cognitive decline and to evaluate genetic factors.

Biomarker evidence has been integrated into the diagnostic criteria for probable and possible AD for use in research settings. (6) Other diagnostic tests for AD include cerebrospinal (CSF) fluid levels of Tau protein or beta-amyloid precursor protein, as well as positron emission tomography (PET) amyloid imaging. The CSF tests are considered separately in policy No. 2.04.14. PET amyloid imaging is considered in policy No. 6.01.55 on Beta Amyloid Imaging with Positron Emission Tomography (PET) for Alzheimer’s Disease.

Regulatory Status

No U.S. Food and Drug Administration (FDA)-cleared genotyping tests were found. The U.S. Food and Drug Administration (FDA) has not regulated these tests to date. Thus, genotyping is offered as a laboratory-developed test. Clinical laboratories may develop and validate tests in-house (“home-brew”) and market them as a laboratory service; such tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA).

Scope

Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply.

Benefit Application

N/A

Rationale

This policy was originally created in 1999 and regularly updated with searches of the MEDLINE database. The most recent literature search was performed for the period of July 2012 through July 2013.

Susceptibility Testing at the Apolipoprotein E (APOE) Gene

The policy regarding apolipoprotein epsilon (APOE) genotyping derives from a 1999 TEC Assessment (9) that offered the following conclusions and observations:

  • Several consensus statements regarding APOE genotyping have been published, which conclude that APOE genotyping in asymptomatic patients, as a technique of risk assessment, is not recommended. Statements regarding its use as a diagnostic test in symptomatic patients are mixed. In 1998, the American College of Medical Genetics/American Society of Human Genetic Working Group on APOE and Alzheimer’s Disease stated, “Studies to date indicate that the APOE genotype alone does not provide sufficient sensitivity or specificity to allow genotyping to be used as a diagnostic test.” In 1997, a National Study Group supported by the National Institutes of Health (NIH) and composed of Alzheimer’s disease (AD) geneticists, policy experts, and ethicists, stated “The use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation.” In contrast, a report by the Working Group on Molecular and Biochemical Markers of Alzheimer’s Disease stated that APOE genotyping can add “confidence to the clinical diagnosis of AD…” but “...the sensitivity and specificity of the epsilon 4 allele alone are low, indicating that this measure cannot be used as the sole diagnostic test for AD.”
  • Considering the published data regarding the sensitivity and specificity of APOE genotyping, the TEC Assessment concluded that the addition of APOE genetic testing does not improve the sensitivity of clinical criteria and only marginally improves the specificity of clinical criteria for the diagnosis of AD. In addition, APOE genetic testing would not alter recommended diagnostic testing for other treatable causes of dementia.

Subsequent to the TEC Assessment, advances in genetic understanding of AD have been considerable (10) with associations between late -onset AD and more than 20 non-APOE genes suggested. However, relevant literature does not provide evidence supporting clinical utility or benefit from genetic testing for AD.

Tsuang et al. (11) prospectively evaluated APOE testing for AD diagnosis in a community-based case series of older patients presenting with memory complaints but no previous diagnosis of dementia. Of 1,028 potential cases, 970 were evaluated; of these, 425 died and 132 were autopsied; of the 132, 71% were confirmed to have AD. The sensitivity and specificity of APOE epsilon 4 alone were poor, yielding positive and negative predictive values of 83% and 41% compared to 81% and 56%, all respectively, for clinical diagnosis alone. Using a criterion of positive clinical diagnosis OR APOE epsilon 4 resulted in positive and negative predictive values of 79% and 70%, respectively. A criterion of positive clinical diagnosis and APOE epsilon 4 improved positive predictive value to 88% but at the expense of negative predictive value (40%). Eleven individuals had an epsilon 4 allele without neuropathologically confirmed AD. While APOE epsilon 4 increases disease susceptibility, it is associated with only approximately 50% of Alzheimer’s cases.

The effect of APOE genotype on response to AD therapy has also been examined. The USA-1 Study group found APOE genotype did not predict therapeutic response. (12) Rigaud et al. followed 117 individuals with AD over 36 weeks in an open-label trial of donepezil; 80 (68%) completed the trial. (13) They found no statistically significant effect of APOE genotype on change in cognition (assessed by ADAS-Cog). However, the study was not designed to examine predictive therapeutic response, and there were baseline cognitive differences according to APOE genotype. There is currently insufficient information to make treatment decisions based on APOE subtype.

The REVEAL Study was designed to examine consequences of AD risk assessment by APOE genotyping. (14) Of 289 eligible participants 162 were randomized (mean age, 52.8 years; 73% female; average education, 16.7 years) to either risk assessment based on APOE testing and family history (n=111) or family history alone (n=51). During a one-year follow-up, those undergoing APOE testing with a high-risk genotype were more likely than low-risk or untested individuals to take more vitamins (40% vs. 24% and 30%, respectively), change diet (20% vs. 11% and 7%, respectively), or change exercise behaviors (8% vs. 4% and 5%, respectively). While in this well-educated sample of women there were some behavior changes, none can be considered a meaningful surrogate endpoint.

Genetic Testing for Early Onset Familial AD

Genetic testing for PSEN1 detects 30-60% of familial early onset AD. A number of mutations have been reported scattered throughout the presenilin 1 (PSEN1) gene, requiring sequencing of the entire gene when the first affected member of a family with an autosomal dominant pattern of AD inheritance is tested. Mutations in APP and PSEN2 genes account for only a small fraction of cases; it is likely that other causative genes will be discovered.

In 1998, The Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics, and Society (15) suggested that “predictive or diagnostic genetic testing for highly penetrant mutations (e.g., APP [amyloid-beta precursor protein], PSEN1, PSEN2 [presenilin 2]) may be appropriate for individuals from families with a clear autosomal dominant pattern of inheritance, particularly those with a family history of early onset of symptoms.” Such families generally have 3 affected members in 2 generations. In the case of diagnostic testing of clearly symptomatic individuals, testing would do little to change diagnostic confidence; however, it might assist excluding other causes of early-onset dementia, as potentially treatable contributory causes would still require exploring. In cases of early detection of questionably symptomatic individuals (i.e., those with mild cognitive impairment) mutation identification might secure a diagnosis and lead to early treatment. The possibility that earlier diagnosis might lead to improved outcomes, while plausible, is not based on current evidence. Pharmacologic interventions for mild cognitive impairment have not demonstrated benefit in reducing progression to AD. (16)

The nearly complete penetrance of a PSEN1 disease-associated mutation would change the probability of developing AD in an unaffected family member from 50% to either 0% or 100%. Testing for PSEN1 mutations is not useful in predicting age of onset (although it is usually similar to age of onset in affected family members), severity, type of symptoms, or rate of progression in asymptomatic individuals. However, identification of asymptomatic, young adult carriers could allow for reproductive planning. Identification of both symptomatic and asymptomatic carriers could also allow for other types of life planning in advance of incapacitating disease.

It is not uncommon to discover previously unreported PSEN1 mutations in an individual, and without additional family information, these may reflect mutations not associated with disease, or new causative mutations restricted to a single family (private mutation). Thus, interpretation of test results of asymptomatic individuals without identification of a mutation in affected family members may be inconclusive in a significant proportion of patients. Should testing be undertaken, affected family members should be tested first or in conjunction with unaffected family members. When no mutation can be identified in affected family members with a clear autosomal dominant pattern of disease inheritance, the family can be referred to a research program for additional study. Any testing should be performed only in the context of adequate pre- and post-test genetic counseling. Finally, it should be noted that pharmacologic therapy for Alzheimer’s disease should be based on the patient’s symptomatology rather than testing results.

GeneTests.org (available online at: www.genetests.org) notes availability of testing for PSEN1, PSEN2, and APP through a number of laboratories.

A systematic review on the psychological and behavioral impact of genetic testing for AD found few studies on the impact of testing for early onset familial AD. The existing studies generally have small sample sizes and retrospective designs, and the research was conducted in different countries, which may limit the generalizability of the findings. (17)

Mihaescu et al. (18) cite a proposed framework by Khoury and colleagues (19) for the continuum of translational research that is required to move genomics research findings in Alzheimer’s disease to clinical and public health applications that benefit population health. The 4 phases of translation research include:

Translation of basic genomics research into a potential health care application;

Evaluation of the application for the development of evidence-based guidelines;

Evaluation of the implementation and use of the application in health care practice; and

Evaluation of the achieved population health impact.

Mihaescu and colleagues conclude that genetic testing for Alzheimer’s disease is still in the first phase. At this point, the sensitivity and specificity of APOE for detecting individuals at risk of developing AD is too low. For those from families with early onset, familial AD, there are currently no known preventive measures or treatments that can mitigate the effect of the disease.

Susceptibility Testing at the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Gene

Jonsson et al. evaluated 3,550 subjects with AD and found a genome-wide association with only one marker, the T allele of rs75932628 (excluding the ApoE locus and the A673T variant in APP11). (4) The frequency of rs75932628 (TREM2) was then tested in a general population of 110,050 Icelanders of all ages and found to confer a risk of AD of 0.63% (odds ratio [OR]: 2.26; 95% confidence interval [CI]: 1.71 to 2.98; p=1.13×10(−8)). In the control population of 8,888 patients 85 years of age or older without a diagnosis of AD, TREM2 frequency was 0.46% (OR: 2.92; 95% CI: 2.09 to 4.09; p=3.42×10(−10)). In 1,236 cognitively intact controls age 85 or older, the frequency of TREM2 decreased even further to 0.31% (OR: 4.66, (95% CI: 2.38 to 9.14; p=7.39×10(−6)). The decrease in TREM2 frequency in elderly patients who are cognitively intact supports the findings associating TREM2 with increasing risk of AD.

Guerriero and colleagues also found a strong association of the R47H TREM2 variant with AD (p=0,001), (5) Using 3 imputed data sets of genome-wide association AD studies, a meta-analysis found a significant association with the variant and disease (p=0.002). The authors further reported direct genotyping of R47H in 1,994 AD patients, and 4,062 controls found a highly significant association with AD (OR: 5.05; 95% CI: 2.77 to 9.16; p=9.0×10(−9)).

No clinical trials were identified that address how the use of the TREM2 rs75932628-T variant might be incorporated into clinical practice.

Ongoing Clinical Trials

A search of online site clinicaltrials.gov on August 24, 2013 identified a number of clinical trials on APOE testing and the clinical manifestations of AD among patients with APOE epsilon 4. No studies on TREM2 were identified.

Summary

Many genes, including APOE and TREM2, have been associated with late-onset Alzheimer’s disease (AD). However, the sensitivity and specificity of these genes is low or unknown for diagnosing AD, and genetic testing has not been shown to add value to the diagnosis of AD made clinically. For individuals with early-onset AD, mutations in the PSEN1 and APP genes are found in a substantial number of patients. However, there is no direct or indirect evidence to establish that clinical outcomes are improved as a result of genetic testing for these mutations.

Therefore, the current evidence does not support genetic testing for AD. The lack of effective methods to prevent the onset of AD or to target AD treatments based on genetic characteristics limits the clinical benefit for such genetic testing. The low sensitivity and specificity of APOE testing for indicating which individuals will progress to AD or as a diagnostic tool, as well as the high likelihood that other genetic findings may affect progression, lend further support to this conclusion. The association of TREM2 and AD has only recently been identified and its clinical utility is unknown. Therefore, genetic testing for AD is considered investigational.

Practice Guidelines and Position Statements

American Academy of Neurology (20)

  • Routine use of APOE genotyping in patients with suspected AD is not recommended at this time (Guideline).
  • There are no other genetic markers recommended for routine use in the diagnosis of AD (Guideline). This guideline is currently being updated (available online at: http://www.aan.com//Guideline/Home/UnderDevelopment ).

European Federation of Neurological Sciences (EFNS) (21)

Recommendations: genetic testing (level of evidence not reported)

Screening for known pathogenic mutations can be undertaken in patients with appropriate phenotype or a family history of an autosomal dominant dementia. Testing of patients with familial dementia and of unaffected at-risk-relatives should be accompanied by neurogenetic counseling and undertaken only after full consent and by specialist centers. Presymptomatic testing may be performed in at-risk members of family-carrying mutation. It is recommended that the Huntington’s disease protocol is followed for pre-symptomatic testing.

Routine Apo E genotyping is not recommended.

Fourth Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)

The 2012 Canadian Consensus Conference on Dementia was held in May 2012 to update the third consensus guidelines referenced below. Previous recommendations were endorsed if there weren’t any changes in the literature. Full articles written by the CCCDTD workgroups providing complete background information for the consensus conference are available online at: http://www.healthplexus.net/article/2012-canadian-consensus-conference-dementia.

A summary of consensus recommendations from the CCCDTD4 was published by Gauthier and colleagues in 2012. (22) It is noted in the summary that: “Despite a large number of important advances, the CCCDTD4 concluded that fundamental changes in dementia diagnosis and management have not yet arrived.” The 2012 CCCDTD4 summary recommends:

“Testing and longitudinal follow-up of asymptomatic individuals or patients with subjective cognitive impairments not meeting MCI [mild cognitive impairment] criteria, or at-risk individuals (e.g., gene mutation carriers, family history of AD, ApoE epsilon 4) should be restricted to research.”

Third Canadian Consensus Conference on Diagnosis and Treatment of Dementia (23)

The third CCCDTD conference recommended the following:

Predictive genetic testing for asymptomatic “at risk” individuals with an apparent autosomal dominant inheritance, and a family-specific mutation has been identified:

  1. With appropriate pre-and post-testing counseling, predictive genetic testing (PGT) can be offered to “at risk” individuals (Grade B, Level 2**). Examples:
  1. First-degree relatives of an affected individual with the mutation (e.g., children and siblings);
  2. First cousins of an affected individual if the common ancestors (parents who were siblings) died before the average age of onset of dementia in the family;
  3. Nieces and nephews of affected individuals whose parent (sibling of the affected individual) died well before the average age of onset of dementia in the family;
  4. PGT in minors is not generally offered in Canada, but occasionally may be considered on a case-by-case basis by the relevant medical ethics committee(s);
  5. Individuals who are not “at risk” for the inherited disease do not require testing.
  1. In young persons (60 years or younger) presenting with an early onset dementia, it is sometimes worthwhile to test for the most common mutations based on the “best estimate” diagnosis (e.g., in early onset AD, one might test for the most common mutations in PS1, APP). (Grade B, Level 2**) If a mutation is identified, it would have direct implications for offspring of the individual (if a de novo mutation is assumed). Conversely, it would also be important to test other family members such as parents and siblings for possible non-penetrance of a mutation.

Genetic screening with APOE genotype in asymptomatic individuals in the general population is not recommended because of the low specificity and sensitivity. (Grade E, Level 2**)

Genetic testing with APOE genotype is not recommended for the purpose of diagnosing AD because the positive and negative predictive values are low.

(Grade E, Level 2**)

**CCCDTD Evidence Ratings

Grade (B) There is fair evidence to support this maneuver.

Grade (E) There is good evidence to recommend against this procedure.

Level 2: (1) Evidence obtained from well-designed controlled trial without randomization, or (2) Evidence obtained from well-designed cohort or case control analytic studies, preferably from more than one center, or (3) Evidence obtained from comparisons between times or places with or without intervention. Dramatic results in uncontrolled experiments are included in this category.

Joint Practice Guidelines of the American College of Genetics and the National Society of Genetic Counselors (2)

  • Pediatric testing for AD should not occur. Prenatal testing for AD is not advised if the patient intends to continue a pregnancy with a mutation.
  • Genetic testing for AD should only occur in the context of genetic counseling (in person or through videoconference) and support by someone with expertise in this area.
  • Symptomatic patients: Genetic counseling for symptomatic patients should be performed in the presence of the individual’s legal guardian or family member.
  • Asymptomatic patients: A protocol based on the International Huntington Association and World Federation of Neurology Research Group on Huntington’s Chorea Guidelines is recommended.
  • DTC APOE testing is not advised.
  • A ≥3-generation family history should be obtained, with specific attention to the age of onset of any neurologic and/or psychiatric symptoms, type of dementia and method of diagnosis, current ages, or ages at death (especially unaffected relatives), and causes of death. Medical records should be used to confirm AD diagnosis when feasible. The history of additional relatives may prove useful, especially in small families or those with a preponderance of early death that may mask a history of dementia.
  • A risk assessment should be performed by pedigree analysis to determine whether the family history is consistent with EOAD [early-onset AD] or LOAD [late-onset AD] and with autosomal dominant (with or without complete penetrance), familial, or sporadic inheritance.
  • Patients should be informed that currently there are no proven pharmacologic or lifestyle choices that reduce the risk of developing AD or stop its progression.
  • The following potential genetic contributions to AD should be reviewed:
  • The lifetime risk of AD in the general population is approximately 10–12% in a 75–80 year lifespan.
  • The effect(s) of ethnicity on risk is still unclear.
  • Although some genes are known, there are very likely others (susceptibility, deterministic, and protective) whose presence and effects are currently unknown.

For families in which an autosomal dominant AD gene mutation is a possibility:

  • Discuss the risk of inheriting a mutation from a parent affected with autosomal dominant AD is 50%. In the absence of identifying a mutation in apparent autosomal dominant families, risk to offspring could be as high as 50% but may be less.
  • Testing for genes associated with early-onset autosomal dominant AD should be offered in the following situations:
  • A symptomatic individual with EOAD in the setting of a family history of dementia or in the setting of an unknown family history (e.g., adoption).
  • Autosomal dominant family history of dementia with one or more cases of EOAD.
  • A relative with a mutation consistent with EOAD (currently PSEN1/2 or APP).
  • The Alzheimer Disease & Frontotemporal Dementia Mutation Database should be consulted (available online at: www.molgen.ua.ac.be/ADMutations/) before disclosure of genetic test results, and specific genotypes should not be used to predict the phenotype in diagnostic or predictive testing.
  • Discuss the likelihood of identifying a mutation in PSEN1, PSEN2, or APP, noting that current experience indicates that this likelihood decreases with lower proportions of affected family members and/or older ages of onset.
  • Ideally, an affected family member should be tested first. If no affected family member is available for testing and an asymptomatic individual remains interested in testing despite counseling about the low likelihood of an informative result (a positive result for a pathogenic mutation), he/she should be counseled according to the recommended protocol. If the affected relative, or their next of kin, is uninterested in pursuing testing, the option of DNA banking should be discussed.

Medicare National Coverage

There is no national coverage determination.

References

  1. Bird TD. Genetic aspects of Alzheimer disease. Genet Med 2008; 10(4):231-9.
  2. Goldman JS, Hahn SE, Catania JW et al. Genetic testing and counseling for Alzheimer’s disease: Joint Practice Guidelines of the American College of Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13(6):597-605.
  3. Caselli RJ, Doeck AC, Locke DE et al. Cerebrovascular risk factors and preclinical memory decline in healthy APOE e4 homozygotes. Neurology 2011; 76(12):1078-84.
  4. Jonsson T, Stefansson H, Steinberg S et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368(2):107-16.
  5. Guerreiro R, Wojtas A, Bras J et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368(2):117-27.
  6. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 263-9. Available online at: http //download.journals.elsevierhealth.com/pdfs/journals/1552-5260/PIIS1552526011001014.pdf. Last accessed September 2013.
  7. Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2012; 2012/01/24:1-13. Available online at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266529/pdf/nihms334821.pdf. Last accessed September 2013.
  8. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 270-9. Available online at: http://download.journals.elsevierhealth.com/pdfs/journals/1552-5260/PIIS155252601100104X.pdf. Last accessed September 2013.
  9. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Genetic Testing for Alzheimer’s Disease: APOE Epsilon 4 Allele. TEC Assessments 1999; Volume 14, Tab 7.
  10. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9(10):768-78.
  11. Tsuang D, Larson EB, Bowen J et al. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Arch Neurol 1999; 56(12-Jan):1489-95.
  12. Raskind MA, Peskind ER, Wessel TGiADamr et al. The Galantamine USA-1 Study Group. Neurology 2000; 54(12):2261-8.
  13. Rigaud AS, Traykov L, Latour F et al. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12(5):415-20.
  14. Chao S, Roberts JS, Marteau TM et al. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord 2008; 22(1):94-7.
  15. McConnell LM, Koenig BA, Greely HT et al. Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society. Nat Med 1998; 4(7):757-9.
  16. Raschetti R, Albanese E, Vanacore N et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007; 4(11):e338.
  17. Rahman B, Meiser B, Sachdev P et al. To know or not to know: An update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer Disease risk. Genet Test Mol Biomarkers 2012; 16(8):1-8.
  18. Mihaescu R, Detmar SB, Cornel MC et al. Translational research in genomics of Alzheimer’s disease: a review of current practice and future perspectives. J Alzheimers Dis 2010; 20(4):967–80.
  19. Khoury MJ, Gwinn M, Yoon PW et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10):665-74.
  20. Knopman DS, DeKosky ST, Cummings JLPpdod et al. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9):1143-53. (reaffirmed 2/13/2004).
  21. Hort J, O’Brien JT, Gainotti G et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010; 17(10):1236–48.
  22. Gauthier S, Patterson C, Chertkow H et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J 2012; 15(4):120-6.
  23. 3rd Canadian Consensus Conference on Diagnosis and Treatment of Dementia (approved July 2007). Available online at: http://www.cccdtd.ca/. Last accessed September 2013.

Coding

Codes

Number

Description

CPT

81405

Molecular pathology procedure, Level 6 (e.g., analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons)

 

81406

Molecular pathology procedure, Level 7 (e.g., analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons, cytogenomic array analysis for neoplasia)

 

81479

Unlisted molecular pathology procedure

ICD-9-Diagnosis

331.0

Alzheimer's disease

ICD-9-Procedure

   

HCPCS

A9270

Noncovered item or service

 

S3852

DNA analysis for APOE epsilon 4 allele for susceptibility to Alzheimer’s disease

 

S3855

Genetic testing for detection of mutations in the presenilin-1 gene

ICD-10-CM
(effective 10/01/14)

F03

Unspecified dementia

 

G30.0 - G30.9

Alzheimer's disease code range

 

G31.1

Senile degeneration of brain, not elsewhere classified

 

R41.0

Disorientation, unspecified

 

R41.81

Age-related cognitive decline

 

Z13.858

Encounter for screening for other nervous system disorders

ICD-10-PCS
(effective 10/01/14)

 

Not applicable. ICD-10-PCS codes are only used for inpatient services.

Type of Service

Pathology/Laboratory

 

Place of Service

Laboratory/Reference Laboratory

 

Appendix

N/A

History

Date

Reason

09/07/99

Add to Medicine Section - New Policy

12/21/00

Replace policy - Coding information added

08/13/03

Replace policy - Policy update; no change in policy statement; CPT codes and references added.

05/10/05

Replace policy - Policy reviewed with literature search; no change to policy statement.

02/06/06

Codes updated - No other changes

05/09/06

Replace policy - Policy reviewed with literature search; information about the CPT codes added to policy guidelines; reference added; no change to policy statement

06/30/06

Update Scope and Disclaimer - No other changes.

05/08/07

Cross References Updated - No other changes.

01/08/08

Replace policy - Policy updated with literature search; no change in policy statement; reference added.

02/10/09

Replace policy - Policy updated with literature search; no change to policy statement. Rational section extensively revised. Code and references added.

02/09/10

Replace policy - Policy updated with literature search; no change to policy statement.

09/14/10

Cross References Updated - No other changes.

08/09/11

Replace policy – Policy updated with literature search; no change in policy statement; reference added.

05/24/12

Policy renumbered to 12.04.13 (previously 2.04.13) and reassigned to new Genetic Testing category.

11/27/12

Replace policy - Policy updated with literature review. References 2-6, 15, 17, 19 added. No change to policy statement. Add Related Policy 6.01.55. CPT codes 81200 – 81479 added effective 1/1/13; code range 83891 – 83912 deleted effective 12/31/12.

01/10/13

Coding update. CPT code 81599, effective 1/1/13, added to policy.

05/18/13

Update Related Policies. Add 12.04.91.

12/04/13

Replace Policy. Policy updated with literature review through July 2013. References 4-5 and 22 added. TREM2 added to investigational policy statement. CPT codes 81405 and 81406 added; 81599 and83914 removed as they are not specific to this policy; 83891 – 83912 removed, as they are now deleted.


Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).
©2014 Premera All Rights Reserved.